1-(tert-butylamino)propan-2-one | 154385-55-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-(tert-butylamino)propan-2-one
• 英文别名: N-tert.-Butylaminoaceton
• CAS: 154385-55-4
• 化学式: C₇H₁₅NO
• mdl: MFCD07801021
• 分子量: 129.202
• InChiKey: UWIRAFQKSOKJOI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(tert-butylamino)propan-2-one 、 三氯硫磷 生成 3-tert-Butyl-2-chloro-5-methyl-3H-[1,3,2]oxazaphosphole 2-sulfide
  参考文献：
  名称：

  BALITSKIJ YU. V.; NEGREBETSKIJ V. V.; GOLOLOBOV YU. G., ZH. OBSHCH. XIMII, 1980, 50, HO 10, 2195-2203

  摘要：

  DOI：
• 作为产物：
  描述：

  溴丙酮 、 叔丁胺 以 乙醚 为溶剂， 生成 1-(tert-butylamino)propan-2-one
  参考文献：
  名称：

  Synthesis and stereochemistry of reduction of N-tert-butyl-5-methyl-3-piperidone

  摘要：

  DOI：

  10.1007/bf00925631

文献信息

• [EN] OXAZOLE OREXIN RECEPTOR ANTAGONISTS<br/>[FR] COMPOSÉS OXAZOLE ANTAGONISTES DES RÉCEPTEURS D'OREXINE
  申请人：MERCK SHARP & DOHME

  公开号：WO2015018029A1

  公开（公告）日：2015-02-12

  The present invention is directed to oxazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the oxazole compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

  本发明涉及氧唑化合物，其为促进睡眠的受体拮抗剂。本发明还涉及所述氧唑化合物在潜在治疗或预防涉及促进睡眠的神经和精神障碍和疾病中的用途。本发明还涉及包含这些化合物的药物组合物。本发明还涉及这些药物组合物在预防或治疗涉及促进睡眠的疾病中的用途。
• [EN] OXAZOLE OREXIN RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DE RÉCEPTEUR D'OREXINE À BASE D'OXAZOLE
  申请人：MERCK SHARP & DOHME

  公开号：WO2015020930A1

  公开（公告）日：2015-02-12

  The present invention is directed to oxazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the oxazole compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

  本发明涉及氧唑化合物，其为促进素受体的拮抗剂。本发明还涉及所述氧唑化合物在潜在的治疗或预防涉及促进素受体的神经和精神障碍和疾病中的用途。本发明还涉及包含这些化合物的药物组合物。本发明还涉及这些药物组合物在预防或治疗涉及促进素受体的疾病中的用途。
• Pyrrolopyridine kinase inhibiting compounds
  申请人：Dong Han-Qing

  公开号：US20070129364A1

  公开（公告）日：2007-06-07

  Compounds represented by Formula (I): or stereoisomers or pharmaceutically acceptable salts thereof, are inhibitors of least one of the Abl, Aurora-A, Blk, c-Raf, cSRC, Src, PRK2, FGFR3, Flt3, Lck, Mek1, PDK-1, GSK3β, EGFR, p70S6K, BMX, SGK, CaMKII, Tie-2, IGF-1R, Ron, Met, and KDR kinases in animals, including humans, for the treatment and/or prevention of various diseases and conditions such as cancer.

  由式（I）表示的化合物或其立体异构体或其药用可接受的盐，是对动物中至少一种Abl、Aurora-A、Blk、c-Raf、cSRC、Src、PRK2、FGFR3、Flt3、Lck、Mek1、PDK-1、GSK3β、EGFR、p70S6K、BMX、SGK、CaMKII、Tie-2、IGF-1R、Ron、Met和KDR激酶的抑制剂，包括人类，用于治疗和/或预防癌症等各种疾病和病况。
• IMIDAZOLOTHIAZOLE COMPOUNDS AND METHODS OF USE THEREOF
  申请人：Apuy Julius L.

  公开号：US20120070410A1

  公开（公告）日：2012-03-22

  Compounds, compositions and methods are provided for modulating the activity of receptor kinases and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by receptor kinases.

  本发明提供了用于调节受体激酶活性的化合物、组合物和方法，并用于治疗、预防或改善由受体激酶介导的一种或多种疾病或障碍的症状。
• OXAZOLE OREXIN RECEPTOR ANTAGONISTS
  申请人：MERCK SHARP & DOHME CORP.

  公开号：US20160176858A1

  公开（公告）日：2016-06-23

  The present invention is directed to oxazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the oxazole compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

  本发明涉及噁唑化合物，其是促进睡眠的荷尔蒙受体的拮抗剂。本发明还涉及这些噁唑化合物在潜在的神经和精神障碍和疾病的治疗或预防中的应用，其中涉及到促进睡眠的荷尔蒙受体。本发明还涉及包含这些化合物的制药组合物。本发明还涉及这些制药组合物在预防或治疗涉及促进睡眠的荷尔蒙受体的疾病中的应用。